"We believe the future of preclinical drug development is patient-relevant, reproducible, and predictive."
We envision a future where every therapeutic entering clinical trials is evaluated in a human-relevant, precisely defined context-of-use system that accurately reflects patient biology.rather than a one-size-fits-all system. As drug development transitions beyond animal models toward New Approach Methodologies (NAMs), Humaniche aims to become the trusted platform for bone marrow-specific translational validation.
By recreating the complexity of the human bone marrow microenvironment, we seek to improve the prediction of efficacy, toxicity, resistance, and treatment response before therapies reach patients. Our goal is to accelerate the development of safer, more effective treatments while reducing costly clinical failures.
Our vision
More than 65 years of combined experience in bioengineering.
Humaniche brings together expertise in bioengineering, bone marrow biology, translational hematology, and entrepreneurship to develop human-relevant bone marrow technologies for the future of preclinical drug development.
The team combines decades of research experience and scientific contributions in AML, MDS, marrow toxicology, and microphysiological systems.
Operational team
Dr. Dilara Perver
co-Founder / CEO
Prof. Dr. Viola Vogel
co-founder / Scientific advisor
Dr. James Bourely
Founder's associate
Structured access for academic and pharma collaborators.
Humaniche supports sponsored research agreements and co-development arrangements with academic labs and pharmaceutical programs. Partners receive defined lot access, characterization data, and direct scientific engagement with the founding team.
